Reaction Biology Corp. products

In collaboration with the bioinformatics firm 4HF Biotech GmbH which is a bioinformatics firm specializing in cancer data mining to discover new anti-cancer drugs, we offer data mining for analysis of the genetic signature of tumor cell lines that are sensitive for a customer drug to reveal potential biomarkers. The Biomarker Analysis is based on the sensitivity profile of the customer compound such as the results of the ProLiFiler - our Cell Line Panel Screening service. The Biomarker Analysis tool identifies genes or genetic alterations which are indicative for the efficacy of a drug and which may serve as predictive biomarkers in disease models and patient cohorts.

ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone methyltransferase domain and has been found to play a role in the regulation of Hox gene expression. Although the ASH1L SET domain has been shown in vitro to methylate histone peptides on lysine-4 of histone H3 (H3K4), ASH1L is an H3K36 methyltransferase both in vivo and in vitro with nucleosomes as substrate.

Human recombinant ASH1L bromodomain. ASH1L is a large (333 kDa), multi-domain protein associated with actively transcribed regions of chromatin. Its bromodomain lies C-terminal to its SET domain, which confers histone H3K36 methyltransferase activity. ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L has been found to play a role in the regulation of Hox gene expression. The ASH1L bromodomain displays strong binding to various Lys(Ac) residues in singly acetylated histone peptide microarrays (histones H1.4K74Ac, H2AK36Ac, H2BK85Ac, H3K56Ac, H4K59Ac/K79Ac).